Loading clinical trials...

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE4

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

NCT03942042•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The reason for this study is to see if the study drug ixekizumab is safe and effective in participants with generalized pustular psoriasis and erythrodermic psoriasis.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Present with GPP or EP based on an investigator-confirmed diagnosis and meet the associated criteria
•* GPP: Meet the criteria for GPP set by Ministry of Health, Labour and Welfare (MHLW) at screening and baseline regardless of IL-36 mutation status.
•* EP: Diagnosed to have BSA ≥80% involvement (with inflammatory erythema) at screening and baseline.
•Candidates for phototherapy and/or systemic therapy
•Men must agree to use a reliable method of birth control during the study
•Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion Criteria

•History of drug-induced psoriasis
•Concurrent or recent use of any biologic agent
•Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
•Have previously received ixekizumab
•Serious disorder or illness other than psoriasis
•Serious infection within the last 12 weeks
•Breastfeeding or nursing (lactating) women

Locations (7)

Nagoya City University Hospital

Nagoya, Aichi-ken, Japan

Tohoku University Hospital

Sendai, Miyagi, Japan

Kansai Medical University Hospital

Hirakata, Osaka, Japan

Teikyo University Hospital

Itabashi-ku, Tokyo, Japan

Jikei University School of Medicine

Minato-Ku, Tokyo, Japan

Tokyo Medical University Hospital

Shinjuku-ku, Tokyo, Japan

Osaka City University Medical School Hospital

Osaka, Japan

Key Dates

Start Date

July 5, 2019

Primary Completion Date

July 22, 2020

Completion Date

July 22, 2020

Last Updated

August 13, 2021

Enrollment

ACTUAL participants

Conditions

Generalized Pustular PsoriasisErythrodermic Psoriasis

Interventions

Ixekizumab

DRUG

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

NCT06477536

Generalized Pustular Psoriasis

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06323356

Generalized Pustular PsoriasisErythrodermic Psoriasis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 13, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Inclusion Criteria

Exclusion Criteria

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis Registry in Costa Rica

Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options